Home › Funds › Duquesne Family Office LLC › PTGX
Duquesne Family Office LLC position in PTGX
PROTAGONIST THERAPEUTICS INC · Health Care
Duquesne Family Office LLC reported holding 208,900 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$25.6M, representing 0.57% of its reported portfolio and ranking #37 among its reported holdings. Duquesne Family Office LLC has disclosed PTGX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Duquesne Family Office LLC's PTGX position evolved
Duquesne Family Office LLC first disclosed a stake in PTGX in Q3 2025 at 159,700 shares (US$10.6M). The position peaked in Q2 2026 at 208,900 shares, worth US$25.6M. Across 4 filings, Duquesne Family Office LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 208,900 shares valued at US$25.6M — an increase of 49,200 shares quarter over quarter.. Notable position changes include a 31% increase in Q2 2026 (shares rose 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 159.70K | $10.61M | New |
| Q4 2025 | 159.70K | $13.95M | Hold |
| Q1 2026 | 159.70K | $16.83M | Hold |
| Q2 2026 | 208.90K | $25.61M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PTGX and 13F data
PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 49 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PTGX
- Farallon Capital Management 6.35M sh · $778.25M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 6.35M sh · $778.25M · Q2 2026
- RTW INVESTMENTS, LP 5.06M sh · $620.40M · Q2 2026
- JOHNSON & JOHNSON 2.45M sh · $300.22M · Q2 2026
- Woodline Partners LP 1.41M sh · $173.35M · Q2 2026
- PERCEPTIVE ADVISORS LLC 981.88K sh · $120.36M · Q2 2026
- ADAR1 Capital Management, LLC 960.86K sh · $117.78M · Q2 2026
- Hood River Capital Management LLC 882.74K sh · $108.21M · Q2 2026
- 683 Capital Management, LLC 290.00K sh · $35.55M · Q2 2026
- Eagle Health Investments LP 248.32K sh · $30.44M · Q2 2026
More on Duquesne Family Office LLC
FAQ
How long has Duquesne Family Office LLC held PTGX?
Duquesne Family Office LLC has disclosed PTGX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Duquesne Family Office LLC's current position in PTGX?
As of Q2 2026, Duquesne Family Office LLC holds 208.90K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $25.61M, representing 0.57% of its reported portfolio and ranking #37.
Has Duquesne Family Office LLC been buying or selling PTGX?
In the latest 13F filing (Q2 2026), Duquesne Family Office LLC increased its position in PTGX. The position peaked in Q2 2026 at 208.90K shares.
Which other funds hold PTGX?
Other major institutional holders of PTGX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.